Prognostic Significance of P53 Expression, Chromosome 17 Copy Number, and DNA Ploidy in Non-metastasized Colorectal Carcinomas (stages IB and II)
Overview
Affiliations
Background And Methods: Paraffin-embedded tumor tissue from 101 non-metastasized colorectal adenocarcinomas (tumor stages IB and II--that is, pT2 and 3, pN0, M0) was investigated for p53 expression by immunohistology (IH) (moab DO1), chromosome 17 (#17) copy number by interphase cytogenetics using non-radioactive in situ hybridization (NISH) with a centromer-specific DNA probe (D17Z1), and DNA ploidy by flow cytometry (FCM). The aims of the study were 1) to test whether numerical #17 aberrations are involved in functional TP53 loss in locally confined colorectal carcinomas; 2) to search for correlations between aberrant p53 expression and #17 aberrations with DNA ploidy and histopathology; and 3) to test the prognostic significance of these factors.
Results: Sixty cases (59.4%) showed nuclear p53 expression IH (low-grade p53 accumulation (< 50%), n = 16 (15.8%); high-grade (> or = 50%), n = 44 (43.6%)). Nish showed #17 aneusomy in 46% of the carcinomas (34% deletions, 12% gains). In FCM analysis, 43% of the carcinomas were DNA non-diploid. p53 overexpression correlated statistically significantly with FCM non-diploidy (p = 0.013). Furthermore, #17 aneusomy also correlated with FCM non-diploidy (p = 0.001). However, there was no association between #17 status and p53 expression (IH).
Conclusions: Our data suggest a role for the TP53 gene in the aneuploidization process. Numerical deletions of #17, however, were not associated with p53 immunoreactivity in the analyzed tumors. With regard to prognosis, the most important independent variable in stage IB/II colorectal carcinomas was tumor stage, followed by high-grade p53 expression of tumor cells; #17 aneusomy was an independent risk factor for tumor relapse/progression but not for survival. As alterations of the investigated variables were not found in all carcinomas under study, different pathogenetic pathways seem to exist in colorectal carcinogenesis.
Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer.
Sarasqueta A, Forte G, Corver W, de Miranda N, Ruano D, van Eijk R BMC Cancer. 2013; 13:277.
PMID: 23739040 PMC: 3682902. DOI: 10.1186/1471-2407-13-277.
Lotter O, Amr A, Safi F Ger Med Sci. 2010; 8:Doc24.
PMID: 21063465 PMC: 2975257. DOI: 10.3205/000113.
Tumour markers of prognosis in colorectal cancer.
McLeod H, Murray G Br J Cancer. 1999; 79(2):191-203.
PMID: 9888457 PMC: 2362193. DOI: 10.1038/sj.bjc.6690033.
[1997 gastroenterology update--I].
Fischbach W, Gro S, Scholmerich J, Ell C, Layer P, Fleig W Med Klin (Munich). 1998; 93(2):70-80.
PMID: 9545704 DOI: 10.1007/BF03043280.